title: Ranibizumab(Lucentis) in high myopia with neovascularization. Better short-term visual acuity but serious adverse effects.
abstract: In a trial versus verteporfin photodynamic therapy, ranibizumab improved visual acuity after 3 months of treatment but had more adverse effects.
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009216:Myopia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000069579:Ranibizumab; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab